SE0100824D0 - Method III to obtain microparticles - Google Patents

Method III to obtain microparticles

Info

Publication number
SE0100824D0
SE0100824D0 SE0100824A SE0100824A SE0100824D0 SE 0100824 D0 SE0100824 D0 SE 0100824D0 SE 0100824 A SE0100824 A SE 0100824A SE 0100824 A SE0100824 A SE 0100824A SE 0100824 D0 SE0100824 D0 SE 0100824D0
Authority
SE
Sweden
Prior art keywords
method iii
microparticles
obtain microparticles
metoprolol
mum
Prior art date
Application number
SE0100824A
Other languages
English (en)
Swedish (sv)
Inventor
Alf Djurle
Mikael Hansson
Malin Soederbom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100824A priority Critical patent/SE0100824D0/xx
Publication of SE0100824D0 publication Critical patent/SE0100824D0/xx
Priority to BR0207919-4A priority patent/BR0207919A/pt
Priority to AU2002235102A priority patent/AU2002235102B2/en
Priority to ES02701873T priority patent/ES2240691T3/es
Priority to AT02701873T priority patent/ATE295153T1/de
Priority to PT02701873T priority patent/PT1370245E/pt
Priority to DE60204125T priority patent/DE60204125T2/de
Priority to EP02701873A priority patent/EP1370245B1/en
Priority to US10/469,907 priority patent/US20040116392A1/en
Priority to DK02701873T priority patent/DK1370245T3/da
Priority to RU2003127739/15A priority patent/RU2292878C2/ru
Priority to JP2002571033A priority patent/JP2004522798A/ja
Priority to PCT/SE2002/000401 priority patent/WO2002072074A1/en
Priority to MXPA03008088A priority patent/MXPA03008088A/es
Priority to CNB028095901A priority patent/CN1236761C/zh
Priority to KR10-2003-7011782A priority patent/KR20030081507A/ko
Priority to HU0303450A priority patent/HUP0303450A2/hu
Priority to PL02363972A priority patent/PL363972A1/xx
Priority to CA002440167A priority patent/CA2440167A1/en
Priority to NZ528168A priority patent/NZ528168A/en
Priority to IL15777702A priority patent/IL157777A0/xx
Priority to SI200230131T priority patent/SI1370245T1/xx
Priority to UA2003098380A priority patent/UA75909C2/uk
Priority to IS6937A priority patent/IS6937A/is
Priority to ZA200306880A priority patent/ZA200306880B/en
Priority to NO20033967A priority patent/NO20033967L/no
Priority to HK04102597A priority patent/HK1059737A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
SE0100824A 2001-03-09 2001-03-09 Method III to obtain microparticles SE0100824D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0100824A SE0100824D0 (sv) 2001-03-09 2001-03-09 Method III to obtain microparticles
SI200230131T SI1370245T1 (xx) 2001-03-09 2002-03-06
PCT/SE2002/000401 WO2002072074A1 (en) 2001-03-09 2002-03-06 Method to prepare microparticles metoprolol that contain
CNB028095901A CN1236761C (zh) 2001-03-09 2002-03-06 含有美托洛尔的微粒的制备方法
ES02701873T ES2240691T3 (es) 2001-03-09 2002-03-06 Metodo para preparar microparticulas que contienen metoprolol.
AT02701873T ATE295153T1 (de) 2001-03-09 2002-03-06 Verfahren zur herstellung von metoprolol enthaltenden mikropartikeln
PT02701873T PT1370245E (pt) 2001-03-09 2002-03-06 Metodo para preparar microparticulas contendo metoprolol
DE60204125T DE60204125T2 (de) 2001-03-09 2002-03-06 Verfahren zur herstellung von metoprolol enthaltenden mikropartikeln
EP02701873A EP1370245B1 (en) 2001-03-09 2002-03-06 Method to prepare microparticles containing metoprolol
US10/469,907 US20040116392A1 (en) 2001-03-09 2002-03-06 Method to prepare microparticles metoprolol that contain
DK02701873T DK1370245T3 (da) 2001-03-09 2002-03-06 Fremgangsmåde til fremstilling af mikropartikler indeholdende metoprolol
RU2003127739/15A RU2292878C2 (ru) 2001-03-09 2002-03-06 Способ приготовления микрочастиц, содержащих метопролол
JP2002571033A JP2004522798A (ja) 2001-03-09 2002-03-06 メトプロロールを含有する微粒子を製造する方法
BR0207919-4A BR0207919A (pt) 2001-03-09 2002-03-06 Método para a preparação de uma micropartìcula homogênea de metoprolol, micropartìcula, composição farmacêutica, método para prevenir ou tratar um distúrbio cardiovascular em um mamìfero, e, uso de uma micropartìcula
MXPA03008088A MXPA03008088A (es) 2001-03-09 2002-03-06 Metodo para preparar microparticulas que contienen metoprolol.
AU2002235102A AU2002235102B2 (en) 2001-03-09 2002-03-06 Method to prepare microparticles that contain metoprolol
KR10-2003-7011782A KR20030081507A (ko) 2001-03-09 2002-03-06 메토프롤롤을 함유하는 미립자의 제조 방법
HU0303450A HUP0303450A2 (hu) 2001-03-09 2002-03-06 Eljárás metoprololt tartalmazó mikrorészecskék előállítására és ezeket tartalmazó gyógyszerkészítmények
PL02363972A PL363972A1 (en) 2001-03-09 2002-03-06 Method to prepare microparticles metoprolol that contain
CA002440167A CA2440167A1 (en) 2001-03-09 2002-03-06 Method to prepare microparticles that contain metoprolol
NZ528168A NZ528168A (en) 2001-03-09 2002-03-06 Method to prepare microparticles metoprolol that contain
IL15777702A IL157777A0 (en) 2001-03-09 2002-03-06 Method to prepare microparticles that contain metoprolol
UA2003098380A UA75909C2 (en) 2001-03-09 2002-06-03 Method for preparation of metoprolol-containing microparticles, pharmaceutical composition for treating cardiovascular diseases
IS6937A IS6937A (is) 2001-03-09 2003-09-03 Aðferð til að framleiða öreindir sem innihalda metóprólól
ZA200306880A ZA200306880B (en) 2001-03-09 2003-09-03 Method to prepare microparticles that contain metoprolol.
NO20033967A NO20033967L (no) 2001-03-09 2003-09-08 Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
HK04102597A HK1059737A1 (en) 2001-03-09 2004-04-14 Method to prepare microparticles containing metroprolol.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100824A SE0100824D0 (sv) 2001-03-09 2001-03-09 Method III to obtain microparticles

Publications (1)

Publication Number Publication Date
SE0100824D0 true SE0100824D0 (sv) 2001-03-09

Family

ID=20283295

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100824A SE0100824D0 (sv) 2001-03-09 2001-03-09 Method III to obtain microparticles

Country Status (25)

Country Link
US (1) US20040116392A1 (xx)
EP (1) EP1370245B1 (xx)
JP (1) JP2004522798A (xx)
KR (1) KR20030081507A (xx)
CN (1) CN1236761C (xx)
AT (1) ATE295153T1 (xx)
AU (1) AU2002235102B2 (xx)
BR (1) BR0207919A (xx)
CA (1) CA2440167A1 (xx)
DE (1) DE60204125T2 (xx)
ES (1) ES2240691T3 (xx)
HK (1) HK1059737A1 (xx)
HU (1) HUP0303450A2 (xx)
IL (1) IL157777A0 (xx)
IS (1) IS6937A (xx)
MX (1) MXPA03008088A (xx)
NO (1) NO20033967L (xx)
NZ (1) NZ528168A (xx)
PL (1) PL363972A1 (xx)
PT (1) PT1370245E (xx)
RU (1) RU2292878C2 (xx)
SE (1) SE0100824D0 (xx)
UA (1) UA75909C2 (xx)
WO (1) WO2002072074A1 (xx)
ZA (1) ZA200306880B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
US8006685B2 (en) * 2002-07-05 2011-08-30 Turbochef Technologies, Inc. Re-circulating oven with gas clean-up
DK1915137T3 (da) 2005-08-10 2013-11-04 Add Advanced Drug Delivery Technologies Ltd Oralt præparat med kontrolleret frisætning
US20070053983A1 (en) * 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
WO2008012346A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
EP2120881B1 (en) * 2007-02-23 2019-08-07 Glatt Air Techniques, Inc. Method of determining the weight of the coating to be applied to form a controlled release dosage form
CN101269056B (zh) * 2007-03-19 2010-05-19 天津药物研究院 一种美托洛尔盐类口服脉冲微丸制剂
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CA2702055C (en) * 2007-10-10 2017-12-12 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CN102641257A (zh) * 2012-03-31 2012-08-22 内蒙古医学院 阿替洛尔缓释微囊及其制备方法
RU2585023C1 (ru) * 2014-12-18 2016-05-27 Общество с ограниченной ответственностью "Нанолек" Способ гранулирования
CN104739805B (zh) * 2015-04-09 2017-12-19 邸蓉 制备琥珀酸美托洛尔缓释微丸的复相乳液法
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
CN115252913A (zh) * 2022-08-02 2022-11-01 赛诺神畅医疗科技有限公司 一种血管给药涂层及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653014A (en) * 1899-10-06 1900-07-03 Ashley & Bailey Company Process of silkifying cotton.
SE354851B (xx) * 1970-02-18 1973-03-26 Haessle Ab
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6221399B1 (en) * 1995-08-17 2001-04-24 Csir Method of making controlled release particles of complexed polymers
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
JP2001519378A (ja) * 1997-10-15 2001-10-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 直接圧縮可能な錠剤化助剤の製造
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
CA2423336C (en) * 2000-09-20 2011-03-08 Rtp Pharma Inc. Stabilised fibrate microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles

Also Published As

Publication number Publication date
ZA200306880B (en) 2004-12-03
HK1059737A1 (en) 2004-07-16
ES2240691T3 (es) 2005-10-16
PL363972A1 (en) 2004-11-29
RU2292878C2 (ru) 2007-02-10
EP1370245A1 (en) 2003-12-17
EP1370245B1 (en) 2005-05-11
NO20033967D0 (no) 2003-09-08
MXPA03008088A (es) 2003-12-12
ATE295153T1 (de) 2005-05-15
HUP0303450A2 (hu) 2004-01-28
UA75909C2 (en) 2006-06-15
NO20033967L (no) 2003-10-28
AU2002235102B2 (en) 2006-08-31
CN1507345A (zh) 2004-06-23
US20040116392A1 (en) 2004-06-17
CN1236761C (zh) 2006-01-18
DE60204125T2 (de) 2006-01-19
WO2002072074A1 (en) 2002-09-19
BR0207919A (pt) 2004-04-27
JP2004522798A (ja) 2004-07-29
IL157777A0 (en) 2004-03-28
CA2440167A1 (en) 2002-09-19
IS6937A (is) 2003-09-03
PT1370245E (pt) 2005-08-31
RU2003127739A (ru) 2005-03-10
KR20030081507A (ko) 2003-10-17
DE60204125D1 (de) 2005-06-16
NZ528168A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
SE0100824D0 (sv) Method III to obtain microparticles
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
MX9805253A (es) Antagonistas del receptor de vitronectina.
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
IL124411A0 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
ZA200306614B (en) Method to obtain microparticles containing a H +, K + -ATP-ase inhibitor.
HU9201789D0 (en) Process for the production of substituted diamino-phtalimides and their analogues
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
IL157540A (en) Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation
BG105275A (en) Tan-1057 derivatives
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE267781T1 (de) Tonzusammensetzung
IL163608A0 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
BR0212504A (pt) Materiais e métodos para vacina de células t autólogas
MXPA04004980A (es) Antagonistas del receptor ccr-3.
HU9801925D0 (en) Sodium-hydrogen-change-inhibitors for producing pharmaceutical compositions for treating diseases caused by protozoons
UY26435A1 (es) Compuestos bis-básicos como inhibidores de triptasa, procedimiento para su preparación y su utilización como medicamentos.
MXPA04000623A (es) Derivados de tetrahidropiridazina y su uso como pesticidas.
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
UA81405C2 (en) Substituted pyridinones as modulators of p38 map kinase
TH62500A (th) Nk1 แอนทาโกนิสท์
IL145017A0 (en) METHOD FOR PRODUCING 4,4-DIMETHYL-3β-HYDROXYPREGNA-8,14-DIENE-21 -CARBOXYLIC ACID ESTERS AND INTERMEDIATE PRODUCTS OBTAINED BY SAID METHOD